SCHEMBL204796

SCHEMBL204796

NC(=O)CC[C@H](N)C(=O)OC(=O)[C@@H](N)CC(N)=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.52
BLM P54132 1/20 0.52
PMP22 Q01453 1/20 0.52
KMT2A Q03164 1/20 0.52
DPP4 P27487 1/20 0.39
DPP8 Q6V1X1 1/20 0.39
DPP9 Q86TI2 1/20 0.39
GRM8 O00222 1/20 0.34
GRM6 O15303 1/20 0.34
GRIN2D O15399 1/20 0.34
GRIN3B O60391 1/20 0.34
GSR P00390 1/20 0.34
CYP1A2 P05177 1/20 0.34
GRIK1 P39086 1/20 0.34
GRM5 P41594 1/20 0.34
GRIA1 P42261 1/20 0.34
GRIA2 P42262 1/20 0.34
GRIA3 P42263 1/20 0.34
SLC1A3 P43003 1/20 0.34
SLC1A2 P43004 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL726834 1.00 ALOX15 (0.52) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL711607 0.92 ALOX15 (0.60) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL9452863 0.89 ALOX15 (0.48) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL5187828 0.89 ALOX15 (0.39) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL5033341 0.89 ALOX15 (0.53) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL17559225 0.88 ALOX15 (0.42) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL11061010 0.87 ALOX15 (0.36) ALOX15BLMPMP22KMT2ADPP9
SCHEMBL995487 0.87 ALOX15 (0.36) ALOX15BLMPMP22KMT2ADPP9
SCHEMBL14486156 0.84 ALOX15 (0.33) ALOX15BLMPMP22KMT2A
SCHEMBL3178198 0.84 ALOX15 (0.52) ALOX15BLMPMP22KMT2ADPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 619 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060040857-A1 1-Desamino-8-a-arginyl vasopressin analogs UNQ TECHNOLOGY TRANSFER LLC. (US) 2006-02-23 US claimed
US-6075141-A N-ALPHA-PROTECTED AMINO ACID ESTER DERIVATIVES ARE USEFUL FOR MAKING PEPTIDES AND POLYPEPTIDES UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2000-06-13 US claimed
CN-117903324-B Pharmaceutical preparation for targeted degradation of hepatitis B virus X protein and application thereof 珠海市人民医院 2024-07-23 CN disclosed
CN-117659116-B Preparation method of tyrosine oligopeptide 珠海瑞德林生物有限公司 2024-05-10 CN disclosed
CN-117903324-A Pharmaceutical preparation for targeted degradation of hepatitis B virus X protein and application thereof 珠海市人民医院 2024-04-19 CN disclosed
WO-2024074847-A1 COMPOSITIONS FOR DETECTING BIOLOGICAL AGENTS PATH SPRAY LTD (GB) 2024-04-11 WO disclosed
WO-2024069175-A1 CLOSTRIDIAL NEUROTOXINS COMPRISING AN ACTIVATING ENDOSOMAL PROTEASE CLEAVAGE SITE IPSEN BIOPHARM LIMITED (GB) 2024-04-04 WO disclosed
WO-2024069176-A1 CLOSTRIDIAL NEUROTOXINS COMPRISING AN ACTIVATING EXOGENOUS PROTEASE CLEAVAGE SITE IPSEN BIOPHARM LIMITED (GB) 2024-04-04 WO disclosed
WO-2024069191-A1 CLOSTRIDIAL NEUROTOXIN FOR USE IN A TREATMENT OF BLADDER PAIN SYNDROME IPSEN BIOPHARM LIMITED (GB) 2024-04-04 WO disclosed
WO-2024057031-A1 CELL-FREE CLOSTRIDIAL NEUROTOXIN ASSAYS IPSEN BIOPHARM LIMITED (GB) 2024-03-21 WO disclosed
CN-117659116-A Preparation method of tyrosine oligopeptide 珠海瑞德林生物有限公司 2024-03-08 CN disclosed
WO-1996020955-A1 PURIFIED THROMBOPOIETIN AND METHOD OF MAKING IT ZYMOGENETICS, INC. (US) 1996-07-11 WO disclosed
WO-1996017067-A1 METHOD FOR SECRETING THROMBOPOIETIN POLYPEPTIDES ZYMOGENETICS, INC. (US) 1996-06-06 WO disclosed
WO-1995021920-A1 HEMATOPOIETIC PROTEIN AND MATERIALS AND METHODS FOR MAKING IT ZYMOGENETICS, INC. (US) 1995-08-17 WO disclosed
US-5428128-A Forming amino acid chain of polypeptide, conjugating non-antigenic polymer to blocking groups, introducing said polymer at each point of synthesis, continuing synthesis of amino acid chain MENSI-FATTOHI NAHLA (US) 1995-06-27 US disclosed
WO-1995000162-A1 SITE SPECIFIC SYNTHESIS OF CONJUGATED PEPTIDES ENZON, INC. (US) 1995-01-05 WO disclosed
CN-1095481-A Measure juvenile cell reagent TOA MEDICAL ELECTRONICS (JP) 1994-11-23 CN disclosed
US-5240602-A Silica solid-support-polyethylene glycol binder-hydrophilic spacer activated coupler ligand CHROMATOCHEM, INC. (US) 1993-08-31 US disclosed
US-5141870-A Transforming plants with mutant fragment confers herbicide resistance E. I. DU PONT DE NEMOURS AND COMPANY (US) 1992-08-25 US disclosed
EP-0105193-A2 Spergualin-related compounds, processes for the preparation thereof and their use as medicaments MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) 1984-04-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040857-A1 1-Desamino-8-a-arginyl vasopressin analogs ARGLU1, AVPR2, AVPR1A ALOX15 3303/4885BLM 3301/4885PMP22 4604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.